Coherus to divest ophthalmology franchise to Sandoz for $170 Million
January 23rd 2024According to the companies, the deal also includes Coherus’ CIMERLI biologics license application, ophthalmology sales and select field reimbursement teams. Coherus will now focus on its oncology business.
Read More
Iuvo BioScience acquires Promedica International
January 21st 2024The combined organization will support all aspects of ophthalmic clinical research, from front of the eye to back of the eye, leveraging an even larger team of experts with centuries of collective experience in ophthalmology.
Read More
According to the company, ABBV-RGX-314 continues to be well tolerated in over 100 patients from three dose levels with no drug-related serious adverse events. The new data was presented at the Hawaiian Eye and Retina meeting in Maui, by John Pitcher, MD, and includes 6-month results from two additional dose level 3 cohorts.
Read More
Eyenovia re-acquires development, commercialization rights to MicroPine in US, Canada
January 16th 2024According to the company, MicroPine, currently in late phase III for pediatric progressive myopia, will complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007.
Read More
Hawaiian Eye and Retina 2024: Toric IOL pearls for correcting lower levels of astigmatism
January 15th 2024David Hutton of Ophthalmology Times talks with William Trattler, MD, about his presentation "Toric IOL pearls for Correcting Lower Levels of Astigmatism" at this year's Hawaiian Eye and Retina 2024 Meeting.
Read More
Jane C. Edmond, MD, starts term as 2024 president of AAO
January 13th 2024According to an American Academy of Ophthalmology news release, Edmond’s priorities during her term include addressing physician and staff shortages and protecting patient safety at a time when nonphysicians are trying to expand their scope of practice into eye surgery.
Read More
Kashani leading Optical Coherence Tomography Angiography Initiative in several multicenter studies
January 12th 2024Studies aim to develop a clinically useful biomarker of retinal capillary changes to monitor the development of a prevalent form of systemic vascular disease and cerebrovascular disease.
Read More
Alcon’s dry eye candidate achieves positive topline results in Phase 3 trials
January 11th 2024AR-15512, a topical transient receptor potential melastatin 8 agonist, is a first-in-class product candidate for the treatment of the signs and symptoms of dry eye disease. Alcon plans to file a New Drug Application for AR-15512 with the FDA in mid-2024.
Read More
New research aims to develop novel therapeutic for glaucoma
January 11th 2024Researchers at Indiana University School of Medicine will focus on providing a foundation for developing a new glaucoma therapeutic by testing human neurons and a regenerative therapy to rescue visual neurons from dying preclinically in human eyes under glaucoma conditions.
Read More
Gentex announces eSight acquisition; will showcase vision technology at CES 2024
January 8th 2024eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.
Read More